Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages
1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany Submitted 19 December 2008 ; accepted in final...
Saved in:
Published in | American journal of physiology: endocrinology and metabolism Vol. 296; no. 5; pp. E1076 - E1084 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.05.2009
|
Subjects | |
Online Access | Get full text |
ISSN | 0193-1849 1522-1555 |
DOI | 10.1152/ajpendo.91013.2008 |
Cover
Loading…
Abstract | 1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany
Submitted 19 December 2008
; accepted in final form 19 February 2009
Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (M -factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M -factor-induced inflammatory responses. M -factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 µM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M -factors (by 13–86%, P < 0.05) and prevented M -factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M -factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 µM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types.
subcutaneous; visceral; adipose; cross talk; inflammation
Address for reprint requests and other correspondence: P. A. Permana, CS/111E, Phoenix Veterans Affairs Health Care System, 650 E. Indian School Rd., Phoenix, AZ 85012-1892 (e-mail: Paska.Permana{at}va.gov ) |
---|---|
AbstractList | Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (Mphi-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and Mphi-factor-induced inflammatory responses. Mphi-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 +/- 13 vs. 56 +/- 7 microM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to Mphi-factors (by 13-86%, P < 0.05) and prevented Mphi-factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to Mphi-factors and monocyte adhesion to Mphi-factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 +/- 7 vs. 150 +/- 15 microM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. 1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany Submitted 19 December 2008 ; accepted in final form 19 February 2009 Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (M -factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M -factor-induced inflammatory responses. M -factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 µM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M -factors (by 13–86%, P < 0.05) and prevented M -factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M -factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 µM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. subcutaneous; visceral; adipose; cross talk; inflammation Address for reprint requests and other correspondence: P. A. Permana, CS/111E, Phoenix Veterans Affairs Health Care System, 650 E. Indian School Rd., Phoenix, AZ 85012-1892 (e-mail: Paska.Permana{at}va.gov ) Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (Mφ-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and Mφ-factor-induced inflammatory responses. Mφ-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 μM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to Mφ-factors (by 13–86%, P < 0.05) and prevented Mφ-factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to Mφ-factors and monocyte adhesion to Mφ-factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 μM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/ macrophages. We show that macrophage factors (M...-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M...-factor-induced inflammatory responses. M...-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 ...M in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M...-factors (by 13 - 86%, P < 0.05) and prevented M...- factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M...-factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 ...M, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. (ProQuest: ... denotes formulae/symbols omitted.) |
Author | Zhang, Weiyang Wabitsch, Martin Fischer-Posovszky, Pamela Reaven, Peter D Permana, Paska A Duckworth, William C |
Author_xml | – sequence: 1 fullname: Permana, Paska A – sequence: 2 fullname: Zhang, Weiyang – sequence: 3 fullname: Wabitsch, Martin – sequence: 4 fullname: Fischer-Posovszky, Pamela – sequence: 5 fullname: Duckworth, William C – sequence: 6 fullname: Reaven, Peter D |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19240250$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUha2qiE4LL8ACRSzYZeqfcRIvUdUCUiVYwNpynJuJR4kdbEcoffreMtMuumBl6fg7x773XJJzHzwQ8oHRLWOSX5vDDL4LW8UoE1tOaXNGNnjBSyalPCcbypQoWbNTF-QypQOltJY7_pZcMMV3lEu6IeNPF_ajy-YBs4sI3WIhFc73o5kmk0NcUUxz8Anl0BfDMhlfmM7Nwa4ZtRyK3lgEU5HARsjQFe1aTMEfgevJ2BjmwewhvSNvejMmeH86r8jvu9tfN9_K-x9fv998uS_tTohcStU2tsUZuhqjpamhgr6Xkgpam0owYRjO33DBQYFVApQBKnvZ1B1veafEFfl8zJ1j-LNAynpyycI4Gg9hSbqqmcRtUQQ_vQIPYYke_6YxXeAjDUPo4wla2gk6PUc3mbjq5yUi0BwBHDSlCL22uNDsgs_RuFEzqp_60qe-9L--9FNfaOWvrC_p_zNtj6bB7Ye_LoKehzW5MIb9-sJzVWmpbxmtK_EIiGis8Q |
CODEN | AJPMD9 |
CitedBy_id | crossref_primary_10_1007_s10522_020_09861_3 crossref_primary_10_1016_j_phrs_2016_02_027 crossref_primary_10_1194_jlr_R024505 crossref_primary_10_3945_jn_109_120022 crossref_primary_10_4137_CMED_S5372 crossref_primary_10_1074_jbc_M109_033951 crossref_primary_10_1371_journal_pone_0077306 crossref_primary_10_1152_ajpcell_00340_2009 crossref_primary_10_1186_1758_5996_6_47 crossref_primary_10_1016_j_bbrc_2010_10_104 crossref_primary_10_1016_j_arcmed_2010_02_010 crossref_primary_10_1074_jbc_M110_123174 crossref_primary_10_1016_j_ijcard_2014_11_099 crossref_primary_10_1016_j_jss_2014_03_007 crossref_primary_10_1016_j_diabres_2015_06_005 crossref_primary_10_3390_nu11030512 crossref_primary_10_1007_s00380_018_1143_3 crossref_primary_10_1017_S0029665109990206 |
Cites_doi | 10.1016/j.amjcard.2003.11.017 10.1038/34178 10.1096/fj.00-0020com 10.1152/ajpendo.00002.2004 10.1161/CIRCULATIONAHA.107.724096 10.2337/diabetes.53.4.1060 10.1172/JCI116821 10.1016/S0140-6736(05)67528-9 10.1210/jc.2002-020135 10.1007/s00125-004-1612-3 10.1210/en.2003-1336 10.2337/db08-0872 10.1093/nar/gng154 10.1038/sj.ijo.0801792 10.1001/jama.286.3.327 10.1074/jbc.M011695200 10.1161/ATVBAHA.108.175687 10.1210/jc.2005-0369 10.1172/JCI200319246 10.1161/01.ATV.0000183883.72263.13 10.1016/j.nut.2003.09.020 10.1016/j.bbrc.2006.01.012 10.1016/j.bbrc.2003.10.013 10.1073/pnas.1031789100 10.1161/01.ATV.0000251608.09329.9a 10.2337/diabetes.53.5.1285 10.1161/01.ATV.0000200226.53994.09 10.1006/meth.2001.1262 10.1210/jc.2006-1465 10.1007/s00125-006-0190-y 10.1194/jlr.M600235-JLR200 10.1016/j.bbrc.2004.04.010 10.1038/sj.ijo.0801520 10.1038/83336 10.1016/j.bbrc.2007.04.092 10.2337/diabetes.51.5.1319 10.2337/diabetes.52.11.2784 10.1074/jbc.M504611200 10.1002/jcb.10565 10.1073/pnas.1133870100 10.2174/187152807780832265 10.1055/s-2007-978682 10.2337/diabetes.54.8.2305 10.1038/sj.ijo.0802853 10.1074/jbc.M706762200 10.1042/bst0290072 10.1161/01.CIR.101.13.1519 10.1172/JCI200319451 10.1074/jbc.M601284200 10.1530/eje.0.1480535 10.1016/S0303-7207(01)00394-X 10.1016/j.cmet.2007.06.010 10.2337/db07-0218 10.1152/ajpendo.90323.2008 10.1074/jbc.M710314200 10.1016/S0014-5793(03)01040-8 10.1016/S0006-291X(03)00418-2 10.1016/S0014-2999(00)00461-1 10.1038/sj.ijo.0802176 10.1038/nsmb.1447 10.1038/nature03988 10.1016/S1043-4666(02)00495-7 10.1074/jbc.M206999200 |
ContentType | Journal Article |
Copyright | Copyright American Physiological Society May 2009 |
Copyright_xml | – notice: Copyright American Physiological Society May 2009 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7TS 7U7 C1K 7X8 |
DOI | 10.1152/ajpendo.91013.2008 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Physical Education Index Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Calcium & Calcified Tissue Abstracts Physical Education Index Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef Toxicology Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1522-1555 |
EndPage | E1084 |
ExternalDocumentID | 1688505461 19240250 10_1152_ajpendo_91013_2008 ajpendo_296_5_E1076 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | - 23M 2WC 39C 4.4 53G 5GY 5VS 8M5 ABPTK ACPRK ADACO ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP C1A DIK DL E3Z EBS EJD F5P GX1 H13 KQ8 O0- OK1 P2P PQEST PQQKQ RAP RHF RHI RPL WH7 WOQ --- 6J9 AAYXX ABJNI BKKCC BTFSW CITATION EMOBN ITBOX P6G RPRKH TR2 W8F XSW YSK CGR CUY CVF ECM EIF NPM 7QP 7TS 7U7 C1K 7X8 |
ID | FETCH-LOGICAL-c433t-59b8cb155d7fac5a7e6eff550307a6313a11158232e9ec93e9ae05f587d2b2d93 |
ISSN | 0193-1849 |
IngestDate | Thu Jul 10 17:14:08 EDT 2025 Mon Jun 30 10:30:22 EDT 2025 Mon Jul 21 05:58:47 EDT 2025 Tue Jul 01 03:18:12 EDT 2025 Thu Apr 24 23:01:52 EDT 2025 Tue Jan 05 17:54:16 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c433t-59b8cb155d7fac5a7e6eff550307a6313a11158232e9ec93e9ae05f587d2b2d93 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 19240250 |
PQID | 232315881 |
PQPubID | 48583 |
ParticipantIDs | proquest_miscellaneous_67150080 highwire_physiology_ajpendo_296_5_E1076 proquest_journals_232315881 crossref_citationtrail_10_1152_ajpendo_91013_2008 crossref_primary_10_1152_ajpendo_91013_2008 pubmed_primary_19240250 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20090501 2009-05-00 2009-May |
PublicationDateYYYYMMDD | 2009-05-01 |
PublicationDate_xml | – month: 05 year: 2009 text: 20090501 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda |
PublicationTitle | American journal of physiology: endocrinology and metabolism |
PublicationTitleAlternate | Am J Physiol Endocrinol Metab |
PublicationYear | 2009 |
Publisher | American Physiological Society |
Publisher_xml | – name: American Physiological Society |
References | R61 R60 R63 R62 R21 R20 R23 R22 R25 R24 R27 R26 R29 R28 R1 R2 R3 R4 R5 R6 R7 R8 R9 R30 R32 R31 R34 R33 R36 R35 R38 R37 R39 R41 R40 R43 R42 R45 R44 R47 R46 R49 R48 R50 R52 R51 R10 R54 R53 R12 R56 R11 R55 R14 R58 R13 R57 R16 R15 R59 R18 R17 R19 |
References_xml | – ident: R12 doi: 10.1016/j.amjcard.2003.11.017 – ident: R42 doi: 10.1038/34178 – ident: R47 doi: 10.1096/fj.00-0020com – ident: R2 doi: 10.1152/ajpendo.00002.2004 – ident: R5 doi: 10.1161/CIRCULATIONAHA.107.724096 – ident: R25 doi: 10.2337/diabetes.53.4.1060 – ident: R17 doi: 10.1172/JCI116821 – ident: R13 doi: 10.1016/S0140-6736(05)67528-9 – ident: R50 doi: 10.1210/jc.2002-020135 – ident: R19 doi: 10.1007/s00125-004-1612-3 – ident: R14 doi: 10.1210/en.2003-1336 – ident: R36 doi: 10.2337/db08-0872 – ident: R56 doi: 10.1093/nar/gng154 – ident: R15 doi: 10.1038/sj.ijo.0801792 – ident: R41 doi: 10.1001/jama.286.3.327 – ident: R32 doi: 10.1074/jbc.M011695200 – ident: R63 doi: 10.1161/ATVBAHA.108.175687 – ident: R10 doi: 10.1210/jc.2005-0369 – ident: R57 doi: 10.1172/JCI200319246 – ident: R51 doi: 10.1161/01.ATV.0000183883.72263.13 – ident: R27 doi: 10.1016/j.nut.2003.09.020 – ident: R40 doi: 10.1016/j.bbrc.2006.01.012 – ident: R30 doi: 10.1016/j.bbrc.2003.10.013 – ident: R58 doi: 10.1073/pnas.1031789100 – ident: R52 doi: 10.1161/01.ATV.0000251608.09329.9a – ident: R9 doi: 10.2337/diabetes.53.5.1285 – ident: R62 doi: 10.1161/01.ATV.0000200226.53994.09 – ident: R34 doi: 10.1006/meth.2001.1262 – ident: R29 doi: 10.1210/jc.2006-1465 – ident: R22 doi: 10.1007/s00125-006-0190-y – ident: R3 doi: 10.1194/jlr.M600235-JLR200 – ident: R44 doi: 10.1016/j.bbrc.2004.04.010 – ident: R55 doi: 10.1038/sj.ijo.0801520 – ident: R8 doi: 10.1038/83336 – ident: R31 doi: 10.1016/j.bbrc.2007.04.092 – ident: R43 doi: 10.2337/diabetes.51.5.1319 – ident: R28 doi: 10.2337/diabetes.52.11.2784 – ident: R38 doi: 10.1074/jbc.M504611200 – ident: R48 doi: 10.1002/jcb.10565 – ident: R45 doi: 10.1073/pnas.1133870100 – ident: R59 doi: 10.2174/187152807780832265 – ident: R6 doi: 10.1055/s-2007-978682 – ident: R11 doi: 10.2337/diabetes.54.8.2305 – ident: R21 doi: 10.1038/sj.ijo.0802853 – ident: R37 doi: 10.1074/jbc.M706762200 – ident: R1 doi: 10.1042/bst0290072 – ident: R46 doi: 10.1161/01.CIR.101.13.1519 – ident: R60 doi: 10.1172/JCI200319451 – ident: R24 doi: 10.1074/jbc.M601284200 – ident: R7 doi: 10.1530/eje.0.1480535 – ident: R18 doi: 10.1016/S0303-7207(01)00394-X – ident: R4 doi: 10.1016/j.cmet.2007.06.010 – ident: R20 doi: 10.2337/db07-0218 – ident: R35 doi: 10.1152/ajpendo.90323.2008 – ident: R49 doi: 10.1074/jbc.M710314200 – ident: R54 doi: 10.1016/S0014-5793(03)01040-8 – ident: R23 doi: 10.1016/S0006-291X(03)00418-2 – ident: R26 doi: 10.1016/S0014-2999(00)00461-1 – ident: R61 doi: 10.1038/sj.ijo.0802176 – ident: R33 doi: 10.1038/nsmb.1447 – ident: R39 doi: 10.1038/nature03988 – ident: R16 doi: 10.1016/S1043-4666(02)00495-7 – ident: R53 doi: 10.1074/jbc.M206999200 |
SSID | ssj0007542 |
Score | 2.0403225 |
Snippet | 1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix,... Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized... |
SourceID | proquest pubmed crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | E1076 |
SubjectTerms | Adhesion Adipocytes - drug effects Adipocytes - immunology Adipokines - biosynthesis Adipokines - genetics Adipose tissue Cell adhesion & migration Cells Chemokine CCL2 - biosynthesis Chemokine CCL2 - genetics Enzyme-Linked Immunosorbent Assay Gene expression Humans Hypoglycemic Agents - pharmacology Infiltration Inflammation Mediators - immunology Inflammation Mediators - metabolism Interleukin-6 - biosynthesis Interleukin-6 - genetics Intra-Abdominal Fat - drug effects Intra-Abdominal Fat - immunology Intra-Abdominal Fat - pathology Macrophages - drug effects Macrophages - immunology Macrophages - secretion Male Middle Aged Molecules Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - biosynthesis RNA, Messenger - genetics Subcutaneous Fat - drug effects Subcutaneous Fat - immunology Subcutaneous Fat - pathology Thiazolidinediones - pharmacology Tissues U937 Cells Vascular Cell Adhesion Molecule-1 - biosynthesis Vascular Cell Adhesion Molecule-1 - genetics |
Title | Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages |
URI | http://ajpendo.physiology.org/cgi/content/abstract/296/5/E1076 https://www.ncbi.nlm.nih.gov/pubmed/19240250 https://www.proquest.com/docview/232315881 https://www.proquest.com/docview/67150080 |
Volume | 296 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiFeELQcoRz7gOABuW28Xq_9WKFUFbQlSIno22p3vYZAYle1g5T8Hf4os4ePqtwvVuL4WGc-z87MzsyH0AtFYqbAwQnyPGNBJEgKepAIMOSSTMkkZ6E2xcmnZ_HxLHp7Ts8Hg--9rKVVLffU5qd1Jf8jVdgHcjVVsv8g2faisAM-g3xhCxKG7V_JeDIvP5km25uyMOwn2cqnV4GUl271_NKlwLrOso6PT2Tzi1Kta9fboeHbqYz5WDtzFMbvDoCRLYXh-PoMWqfq27HtQk-v84QNkrjiF0P3U2QlaKSi6_G01DUgbtH0LLT62JQsCGfJVl9FF1ht49gf9Xwt_Oxq4_5yXleOvsp1QGgBOK8M_oJJWZXfqo0LCU_EUi_ElchG2uURNsHOlATggaZ9bR06AlwPS9rTvWPwZOPeRA7fHfvc9VmCmq6z4othGS73wGAaEZtV282JTR7A2Xt-NDs54dPx-fQGuhmCL2K0_7sPXUt6QyHsavLdYJvKLBruX7_DVeun6Uj9a-_GWjnTu-iOd0_wocPaPTTQxTbaOSwATcs1foknrYy30a1Tn5exgxZ9JGKPRNxHIm6RiMscWyTiDom4LrFHIm6QiOUat0jc7-HwPpodjadvjgPP4xGoiJA6oKlMlATDNWNwKSqYjnWeg2sM84uIyYgImHBpAra9TrVKiU6FPqA5TVgWyjBLyQO0VcDwHyFMlR7FpqiJ5SySUSJVBvpFZgnTjOmIDNGo-X-58k3uDdfKgltnl4bcy4RbmVgS1iF63Z5z4Vq8_PboV43YePdetQcCPDnlFopDtNtIlfuXseLwkASeNRkN0fP2V9DoZplOFLpcVTxm4KSBIzdEDx0UulGlZi2UHjz-47m76Hb3Rj1BW_XlSj8F67mWzyx6fwAIwtAF |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pioglitazone+reduces+inflammatory+responses+of+human+adipocytes+to+factors+secreted+by+monocytes%2Fmacrophages&rft.jtitle=American+journal+of+physiology%3A+endocrinology+and+metabolism&rft.au=Permana%2C+Paska+A&rft.au=Zhang%2C+Weiyang&rft.au=Wabitsch%2C+Martin&rft.au=Fischer-Posovszky%2C+Pamela&rft.date=2009-05-01&rft.issn=0193-1849&rft.volume=296&rft.issue=5&rft.spage=E1076&rft.epage=E1084&rft_id=info:doi/10.1152%2Fajpendo.91013.2008&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0193-1849&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0193-1849&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0193-1849&client=summon |